BEIJING--(BUSINESS WIRE)--Sep 3, 2025-- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and Merck KGaA, Darmstadt, Germany, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated lipid nanoparticle (LNP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903434045/en/ Under the terms of the agreement, Biocytogen will provide proprietary, fully human antibodies derived from its RenMice ® platform for evaluation in Merck KGaA, Darmstadt, Germany’s antibody-conjugated LNP services.